Abstract
We have recently reported that administration of Pro Tα to DBA/2 mice before the inoculation of syngeneic L1210 leukemic cells prolonged the survival of these animals by (a) inducing tumoricidal peritoneal macrophages, (b) enhancing natural killer (NK) and inducing lymphokine-activated killer (LAK) activities in splenocytes and (c) inducing the production of interleukin-2 and tumor necrosis factor α [Papanastasiou et al. (1992) Cancer Immunol Immunother 35:145; Baxevanis et al. (1994) Cancer Immunol Immunother 38:281]. In this report we demonstrate that Pro T α, when administered simultaneously with L1210 tumor cells, is capable of generating in DBA/2 animals tumorspecific CD8+ cytotoxic T lymphocytes (CTL). The Pro T α-induced CD8+ CTL lysed their syngeneic L1210 targets in a major histocompatibility complex (MHC)-restricted fashion since monoclonal antibodies (mAb) against the H-2Kd allelic product could inhibit the cytotoxic response. Mice receiving only Pro T α developed non-MHC-restricted cytotoxic activity (NK, and LAK activities) whereas those receiving Pro T α and L1210 tumor cells developed both MHC-restricted (CTL) and non-MHC-restricted cytotoxic activities and survived longer. The Pro T α-induced CD8+ CTL activity was regulated by Pro T α-induced L1210-specific syngeneic CD4+ cells. This was shown in two different ways: first, CD8+-cell-mediated cytotoxic responses against L1210 targets were associated with L1210-specific and MHC-restricted proliferative responses of syngeneic CD4+ cells and, second, CD4+ cells from mice that had received both Pro T α and L1210 tumor cells could enhance in vitro the otherwise weak, MHC-restricted and L1210-specific cytotoxicity of syngeneic CD8+ cells from mice that had received only L1210 cells. Our data suggest that Pro T α is capable of inducing nonspecific, as well as tumor-specific CTL responses in vivo. This is of importance since Pro T α may prove to be useful in clinical protocols aimed at cancer immunotherapy.
Similar content being viewed by others
References
Asher A, Mule JJ, Reichert CM, Shiloni E, Rosenberg SA (1987) Studies on the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo. J Immunol 138:963
Baxevanis CN, Papamichail M (1994) Characterization of the anti-tumor immune response in human cancers and strategies for immunotherapy. Crit Rev Oncol Hematol 16:57
Baxevanis CN, Ishii N, Nagy ZA, Klein J (1982) H-2-controlled suppression of T cell response to lactate dehydrogenase B. Characterization of the lactate dehydrogenase B suppressor pathway. J Exp Med 156:822
Baxevanis CN, Reclos GJ, Papamichail M, Tsokos GC (1987) Prothymosin α restores the depressed autologous and allogeneic mixed lymphocyte reaction in patients with systemic lupus erythematosus. Immunopharmacol Immunotoxicol 9:429
Baxevanis CN, Reclos GJ, Paneerselvam M, Papamichail M (1988) Enhancement of human T lymphocyte functions by prothymosin α. I. Augmentation of mixed lymphocyte culture reactions and soluble protein-induced proliferative responses. Immunopharmacology 15:73
Baxevanis CN, Anastasopoulos E, Reclos GJ, Papamichail M (1990) Prothymosin α enhances HLA-DR antigen expression on monocytes from patients with multiple sclerosis. J Neuroimmunol 27:140
Baxevanis CN, Reclos GJ, Papamichail M (1990) Decreased HLA-DR antigen expression on monocytes causes impaired suppressor cell activity in multiple sclerosis. J Immunol 144:4166
Baxevanis CN, Thanos D, Reclos GJ, Anastasopoulos E, Tsokos GC, Papamatheakis J, Papamichail M (1992) Prothymosin α enhances human and murine major histocompatibility complex class II surface antigen expression and mRNA accumulation. J Immunol 148:1979
Baxevanis CN, Reclos GJ, Papamichail M (1993) Prothymosin α restores depressed allogeneic cell-mediated lympholysis and natural killer cell-activity in patients with cancer. Int J Cancer 53:264
Baxevanis CN, Reclos GJ, Gritzapis AD, Dedoussis GVZ, Missitzis I, Papamichail M (1993) Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer 72:491
Baxevanis CN, Gritzapis AD, Dedoussis GVZ, Papadopoulos NG, Papamichail M (1994) Induction of lymphokine-activated killer activity in mice by prothymosin α. Cancer Immunol Immunother 38:281
Blankenstein T, Quin Z, Ueberla K, Mueller W, Rosen H, Volk HD, Diamanstein T (1991) Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J Exp Med 173:1047
Cordero OJ, Sarandeses C, Nogueira M (1994) Prothymosin α receptors on peripheral blood mononuclear cells. FEBS Lett 341:23
Eschenfeldt WH, Berger SL (1986) The human prothymosin α gene is polymorphic and induced upon growth stimulation: evidence using a cloned cDNA. Proc Natl Acad Sci USA 83:9
Goodall GJ, Dominquez F, Horecker BL (1986) Molecular cloning of cDNA for human prothymosin α. Proc Natl Acad Sci USA 83:8926
Haritos AA, Goodall GJ, Horecker BL (1984) Prothymosin α: isolation and properties of the major immunoreactive form of th6mosin α1 in rat thymus. Proc Natl Acad Sci USA 81:1008
Haritos AA, Tsolas O, Horecker BL (1984) Distribution of prothymosin α in rat tissues. Proc Natl Acad Sci USA 81:1391
Haritos AA, Salvin BB, Blacher R, Stein S, Horecker BL (1985) Parathymosin α: a peptide from rat tissues with structural homology to prothymosin α. Proc Natl Acad Sci USA 82:1050
Ioannides GC, Whiteside TL (1993) T cell recognition of human tumors: implications for molecular immunotherapy of cancer. Clin Immunol Immunopathol 66:91
Melief CJM (1992) Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res 58:43
Mukherji B, Chakraborty NG, Sivanandham M (1990) T-cell clones that react against autologous human tumors. Immunol Rev 116:33
Mule JJ, Custer MC, Travis WD, Rosenberg SA (1992) Cellular mechanisms of the antitumor activity of recombinant IL-6 in mice. J Immunol 148:2622
Pan LX, Haritos AA, Wideman J, Kamiyama T, Chang M, Stein S, Salvin SB, Horecker BL (1986) Human prothymosin α: amino acid sequence and immunologic properties. Arch Biochem Biophys 250:197
Papamichail M, Baxevanis CN (1992) Gamma-interferon enhances the cytotoxic activity of interleukin-2-induced peripheral blood lymphocyte (LAK) cells, tumor-infiltrating lymphocytes (TIL), and effusion-associated lymphocytes. J Chemother 4:387
Papanastasiou M, Baxevanis CN, Papamichail M (1992) Promotion of murine antitumor activity by prothymosin α treatment. I. Induction of tumoricidal peritoneal cells producing high levels of tumor necrosis factor-α. Cancer Immunol Immunother 35:145
Pfizenmaier K, Scheurich P, Schulueter C, Kroenke M (1987) Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol 138:975
Restifo N, Spiess P, Karp S, Mule J, Rosenberg SA (1992) A nonimmunologic sarcoma transduced with the cDNA for interferon γ elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability. J Exp Med 175:1423
Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180
Tepper R, Pattengale P, Leder P (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 57:503
Author information
Authors and Affiliations
Additional information
This work was supported by a CEC grant to Dr. M. Papamichail
Rights and permissions
About this article
Cite this article
Baxevanis, C.N., Gritzapis, A.D., Spanakos, G. et al. Induction of tumor-specific T lymphocyte responses in vivo by prothymosin α. Cancer Immunol Immunother 40, 410–418 (1995). https://doi.org/10.1007/BF01525392
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01525392